UCLA trial shows promising results for off-the-shelf cancer vaccine

Researchers at UCLA Health Jonsson Comprehensive Cancer Center have reported promising results from a trial of a novel off-the-shelf cancer vaccine known as ELI-002 2P. This vaccine targets KRAS mutations, prevalent in pancreatic and colorectal cancers, which are among the most challenging malignancies to treat. Published on October 12, 2026, in Nature Medicine, the study involved 25 patients and highlighted the vaccine's ability to elicit strong and durable immune responses, potentially improving patient outcomes and preventing cancer recurrence. The study revealed that 84% of the participants generated specific T cells targeting KRAS mutations. These results are particularly significant given the historical difficulties in treating cancers associated with KRAS mutations, which account for a substantial proportion of pancreatic and colorectal cancers.

After an extensive follow-up period of 19.7 months, the median relapse-free survival was reported at 16.33 months, with overall survival reaching 28.94 months. These figures surpass historical norms, indicating a potential breakthrough in cancer treatment. Patients who developed robust immune responses to the vaccine experienced even more favorable outcomes. Notably, those with strong T-cell responses showed significantly longer relapse-free survival, with the median not reached compared to just 3.02 months for those with weaker responses. This suggests that the vaccine not only activates the immune system but also has the potential to sustain its response against cancer cells over time, offering hope for those at high risk for recurrence.

The ELI-002 2P vaccine is notable for being an off-the-shelf product, designed to be administered without the need for personalized modifications for each patient. This contrasts sharply with traditional cancer therapies that often require customization based on individual patient profiles and specific tumor characteristics. The vaccine utilizes innovative amphiphile technology to deliver antigens directly to lymph nodes, which enhances the immune response. This method may streamline the treatment process, making it more accessible to patients.

Looking to the future, the research team has completed enrollment for a larger Phase 2 study of ELI-002 7P, a next-generation version of the vaccine that aims to target a broader range of KRAS mutations. This ongoing research underscores the potential of ELI-002 to transform cancer treatment paradigms by providing a standardized, effective approach to managing KRAS-driven cancers. As the scientific community continues to explore this avenue, the findings from this trial may pave the way for more effective cancer therapies and improved patient outcomes across the board.